First-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in patients with multiple myeloma. ICPOEP 2015

Kristian Thidemann Andersen, Maja Hinge, Erik Kay Segel, Tina Ormstrup, Paw Holdgaard, Niels Pallisgaard, Gitte Birk Kerndrup, Torben Plesner

Publikation: Konferencebidrag uden forlag/tidsskriftPosterForskningpeer review

OriginalsprogEngelsk
Publikationsdatonov. 2015
StatusUdgivet - nov. 2015
Begivenhed2nd International Conference on Phase One and Early Phase Clinical Trials (ICPOEP) - Hong Kong, Hong Kong
Varighed: 20. nov. 201521. nov. 2015

Konference

Konference2nd International Conference on Phase One and Early Phase Clinical Trials (ICPOEP)
LandHong Kong
ByHong Kong
Periode20/11/201521/11/2015

Citer dette

Andersen, K. T., Hinge, M., Segel, E. K., Ormstrup, T., Holdgaard, P., Pallisgaard, N., ... Plesner, T. (2015). First-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in patients with multiple myeloma. ICPOEP 2015. Poster session præsenteret på 2nd International Conference on Phase One and Early Phase Clinical Trials (ICPOEP), Hong Kong, Hong Kong.
Andersen, Kristian Thidemann ; Hinge, Maja ; Segel, Erik Kay ; Ormstrup, Tina ; Holdgaard, Paw ; Pallisgaard, Niels ; Kerndrup, Gitte Birk ; Plesner, Torben. / First-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in patients with multiple myeloma. ICPOEP 2015. Poster session præsenteret på 2nd International Conference on Phase One and Early Phase Clinical Trials (ICPOEP), Hong Kong, Hong Kong.
@conference{f9a9529dac5d4147a388aa02a6fb5aeb,
title = "First-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in patients with multiple myeloma. ICPOEP 2015",
author = "Andersen, {Kristian Thidemann} and Maja Hinge and Segel, {Erik Kay} and Tina Ormstrup and Paw Holdgaard and Niels Pallisgaard and Kerndrup, {Gitte Birk} and Torben Plesner",
year = "2015",
month = "11",
language = "English",
note = "null ; Conference date: 20-11-2015 Through 21-11-2015",

}

Andersen, KT, Hinge, M, Segel, EK, Ormstrup, T, Holdgaard, P, Pallisgaard, N, Kerndrup, GB & Plesner, T 2015, 'First-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in patients with multiple myeloma. ICPOEP 2015' 2nd International Conference on Phase One and Early Phase Clinical Trials (ICPOEP), Hong Kong, Hong Kong, 20/11/2015 - 21/11/2015, .

First-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in patients with multiple myeloma. ICPOEP 2015. / Andersen, Kristian Thidemann; Hinge, Maja; Segel, Erik Kay; Ormstrup, Tina; Holdgaard, Paw; Pallisgaard, Niels; Kerndrup, Gitte Birk; Plesner, Torben.

2015. Poster session præsenteret på 2nd International Conference on Phase One and Early Phase Clinical Trials (ICPOEP), Hong Kong, Hong Kong.

Publikation: Konferencebidrag uden forlag/tidsskriftPosterForskningpeer review

TY - CONF

T1 - First-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in patients with multiple myeloma. ICPOEP 2015

AU - Andersen, Kristian Thidemann

AU - Hinge, Maja

AU - Segel, Erik Kay

AU - Ormstrup, Tina

AU - Holdgaard, Paw

AU - Pallisgaard, Niels

AU - Kerndrup, Gitte Birk

AU - Plesner, Torben

PY - 2015/11

Y1 - 2015/11

M3 - Poster

ER -

Andersen KT, Hinge M, Segel EK, Ormstrup T, Holdgaard P, Pallisgaard N et al. First-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in patients with multiple myeloma. ICPOEP 2015. 2015. Poster session præsenteret på 2nd International Conference on Phase One and Early Phase Clinical Trials (ICPOEP), Hong Kong, Hong Kong.